Maytansinoid B 

Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form Antibody-Drug Conjugates (ADCs). Maytansinoids are known as antimitotic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis^[1][2].

Maytansinoids exhibits cytotoxic activity with 10-90 pM range across several tumor cell lines, including lymphoma lines^[1].
Maytansinoid conjugates with anti-CD9, to form SAR3419 against B-cell malignancies^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

735.26

Solid

C₃₆H₅₁ClN₄O₁₀

1628543-40-7

O=C(N(C)[[email protected]@H](C)C(O[[email protected]]([[email protected]@]1(C)[[email protected]@H](O1)[[email protected]@H]2C)CC(N(C)C3=C(Cl)C(OC)=CC(C/C(C)=C/C=C/[[email protected]@H](OC)[[email protected]]4(O)NC(O[[email protected]]2C4)=O)=C3)=O)=O)CCNC

Room temperature in continental US; may vary elsewhere.

• [1]. Blanc V, et al. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011 Oct 15;17(20):6448-58.  [Content Brief]

  [2]. Andreev Julian, et al. Bispecific antigen binding molecules that bind HER2, and methods of use thereof: World Intellectual Property Organization, WO2021174113. 2021-09-02.